MedTrace Logo

Cannabidiol for Treatment of Non-affective Psychosis and Cannabis Use

NCT04105231 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-01-27

No results posted yet for this study

Summary

This trial examines the efficacy of cannabidiol (CBD) versus risperidone for treatment of psychosis in patients with non affective-psychosis and lifetime use of cannabis.

Conditions

  • Dual Diagnosis

Interventions

DRUG

Cannabidiol

Cannabidiol oral suspension

DRUG

Risperidone

Risperidone, encapsulated tablet.

Sponsors & Collaborators

  • Danish Center for Sleep Medicine

    collaborator OTHER

  • Copenhagen University Hospital, Denmark

    collaborator OTHER

  • Glostrup University Hospital, Copenhagen

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • Lone Baandrup

    lead OTHER

Principal Investigators

  • Lone Baandrup, MD, PhD · Mental Health Services Capital Region in Denmark

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-01
Primary Completion
2025-11-25
Completion
2026-03-31

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04105231 on ClinicalTrials.gov